Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis

Condition:   Aortic Valve Stenosis
Interventions:   Device: SAPIEN 3;   Procedure: SAVR
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2016

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified July 2016

Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Device: Single lead ECG device;   Device: 7-Day Holter monitor.
Sponsors:   Leiden University Medical Center;   Medical Center Haaglanden;   Groene Hart Ziekenhuis;   Herning Hospital;   Bronovo Hospital
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified July 2016

Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study

Condition:   Stroke
Intervention:  
Sponsors:   Xuanwu Hospital, Beijing;   The First Affiliated Hospital of Shanxi Medical University;   Liaocheng Brains Hospital;   Tianjin Huanhu Hospital;   Baotou City Central Hospital;   First Hospital of Jilin University;   First Affiliated Hospital of Harbin Medical University;   First Hospital of China Medical University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   The First Affiliated Hospital of Soochow University;   Anhui Provincial Hospital;   Guangdong Provincial Hospital of Traditional Chinese Medicine;   ZhuHai Hospital;   Fujian Provincial Hospital;   Mianyang Central Hospital;   The Second Affiliated Hospital of Kunming Medical University;   Brains Hospital of Hunan Province;   Henan Provincial Hospital;   Luoyang Central Hospital;   National Health and Family Planning Commission Stroke Prevention Engineering Committee;   Dalian Municipal Central Hospital
Completed - verified July 2016

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified July 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Completed - verified July 2016

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Conditions:   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Drug: Rivaroxaban;   Drug: Warfarin
Sponsors:   Asan Medical Center;   Bayer
Completed - verified July 2016

Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors

Conditions:   Ischemic White Matter Disease;   Transient Ischemic Attack;   Mild Stroke;   Stroke Risk
Interventions:   Behavioral: Executive Function Training Program;   Behavioral: Psychoeducational Training Program
Sponsors:   Baycrest;   Sunnybrook Health Sciences Centre
Recruiting - verified July 2016

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Condition:   Peripheral Endovascular Interventions
Intervention:   Drug: Bivalirudin
Sponsor:   The Medicines Company
Active, not recruiting - verified July 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified July 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Conditions:   Carotid Stenosis;   Atherosclerosis;   Stroke;   Transient-ischaemic Attack;   TIA;   Amaurosis Fugax
Interventions:   Drug: Revacept;   Drug: Placebo
Sponsor:   AdvanceCor GmbH
Recruiting - verified July 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified July 2016